Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours.
Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines.
In the early days of SARS-CoV-2 infection in the lungs, what happens at the single-cell level?
A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.
Biomedical engineers at Duke University have devised a test to quickly and easily assess how well a person's neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant.
The cell plasma membrane and the derived endosomal membranes are both greasy barriers that prevent the inflow of water-soluble macromolecules like nucleic acids and proteins into cells.
Sphere Fluidics announced today that it has closed a $40 million (circa £30 million) investment round.
The reason why some people age worse than others and develop diseases linked to the aging mechanism is largely unknown.
Researchers identified a greatly potent monoclonal antibody that aims at the spike protein of SARS-CoV-2.
AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.
Scientists at La Jolla Institute for Immunology have published a detailed map of where human antibodies bind to SARS-CoV-2, a map that was generated by a global collaboration comparing nearly all leading clinical candidates.
Recent research indicates that a familiar inflammatory skin condition might arise due to inadequately regulated sex hormones.
In recent years, scientists have developed monoclonal antibodies -; proteins that mimic the body's own immune defenses -; that can combat a variety of diseases, including some cancers and autoimmune disorders such as Crohn's disease.
Recently, Prof. XIE Can from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science (HFIPS), in a collaboration with Prof. YAN Xiyun's lab from the Institute of Biophysics, reported the structural basis of mAb AA98's inhibition on CD146-mediated endothelial cells (EC) activation and designed higher affinity monoclonal antibody HA98 for cancer treatment.
Recently, researchers achieved a crucial discovery that could mitigate and eliminate immune responses causing treatment failure in people with hemophilia A.
The results of a study led by Northern Arizona University and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest the immune systems of people infected with COVID-19 may rely on antibodies created during infections from earlier coronaviruses to help fight the disease.
According to the results of a study, the immune systems of COVID-19 patients may depend on antibodies that were produced during infections from previous coronaviruses to help combat the disease.
Proteogenomic studies may provide a better understanding of how to match cancer patients with an effective treatment for their specific cancer.
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.